Is Melanotan-1 Safe? Safety Profile 2026 — PeptidePrices

Q: Is Melanotan-1 safe?

Melanotan-1 has a safety rating of 8/10 in our methodology — good. FDA/EMA approved for EPP; nausea, headache mild; selective MC1R agonist; well-studied

Q: Is Melanotan-1 FDA approved?

FDA status: FDA-approved (Scenesse). PeptidePrices does not sell or recommend any compound for human use; this information is for research-context only.

Q: Where can I find verified Melanotan-1?

PeptidePrices tracks live prices and COA verification status across 30+ vendors. See our cheapest Melanotan-1 listings for prices ranked by COA tier and $/mg.

Safety Profile

Melanotan-1

Updated today

Melanocortin Peptide

8/10Good

How we score compound safety →

Primary use: Melanocortin / photoprotection research

Regulatory Status

FDA-approved (Scenesse)

Safety Summary

FDA/EMA approved for EPP
nausea, headache mild
selective MC1R agonist
well-studied

Melanotan-1 sits in our well-studied tier (8/10). The safety dataset is robust, mechanisms are characterized, and side-effect patterns are predictable. Researchers working with this compound should still verify vendor COA quality — a clean safety profile means nothing if the vial contains the wrong compound or is under-dosed. Researchers often consider Melanotan-2 and PT-141 as alternatives in the same category — see the related-compounds section below for safety comparisons.

Molecular Profile

TypeSynthetic linear peptide

Molecular Weight1,646.8 g/mol

Amino Acids13

CAS Number75921-69-6

SequenceAc-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂

FormulaC₇₈H₁₁₁N₂₁O₁₉

Storage

Lyophilized2–8°C, stable for years

Reconstituted2–8°C, within 30 days

Store refrigerated
Protect from light
Reconstitute with bacteriostatic water

Related Compounds

Methodology

How we rate peptide safety

Every compound in our index gets a 1–10 safety score based on four weighted factors. The score reflects known research-use risk — not medical advice.

40% — Clinical evidence. Volume of peer-reviewed trials, sample sizes, duration, and consistency of outcomes. FDA-approved compounds anchor the top end (8–10); preclinical-only compounds cap at 6.
30% — Adverse-event profile. Severity and frequency of reported side effects, including GI events, cardiovascular signals, hypoglycemia, and long-term organ effects.
20% — Regulatory status. FDA approval, EMA approval, or status in active clinical trials. Compounds under safety warnings are penalized.
10% — Community-reported outcomes. Reddit, forum, and published case-report signal beyond formal trials. Used as a late-stage tiebreaker, not a leading factor.

9–10Well-studied, FDA-approvedLarge-trial evidence, established long-term safety. Examples: semaglutide, tesamorelin at approved doses.

7–8Mostly safe, some caveatsPhase 2/3 evidence or long community track record with known manageable side effects. Routine monitoring recommended.

5–6Mixed dataLimited clinical trials, mostly community/preclinical data. Real but uncertain risk profile.

3–4Caution advisedKnown side-effect patterns, thin safety data, or compounds under active regulatory scrutiny.

1–2Significant risk signalsDocumented serious adverse events (cardiovascular, hepatotoxicity, contamination) or withdrawn regulatory status.

Related compounds

Other compounds researchers compare with Melanotan-1

Full Melanotan-1 profile Cheapest Melanotan-1 deals

Safety ratings are derived from published clinical data, FDA approval status, and community-reported outcomes. They are not medical advice. Always consult a healthcare professional before using any research compound.